Ramosetron
As of the edition of 20 October 2026, Ramosetron is a small molecule: marketed, first approved in 1996 (JP); acts on HTR3A, HTR3B and HTR3C and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1996
- Kind
- Small molecule
- Brand name
- Irribow
- First approved
- 10 July 1996 (JP)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Astellas
- Registered trials
- 44, 0 stopped early
- Disease areas
- Digestive system; Cancer; Urinary and reproductive; Blood and lymph; Bones, joints and muscles; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Ramosetron.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 14 | 11 | 1 | 0 |
| Phase 1 | 3 | 2 | 0 | 0 |
| Phase 2 | 6 | 4 | 0 | 0 |
| Phase 3 | 8 | 6 | 0 | 0 |
| Phase 4 | 13 | 8 | 1 | 0 |
| All trials | 44 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Astellas | Originator and Lead sponsor of trials | 1996 to now |